Navigation Links
Envera Files Patent for Low Temperature Growing Bacteria
Date:11/21/2013

West Chester, PA (PRWEB) November 21, 2013

Envera announced today the filing of a patent covering a proprietary group of low temperature growing bacteria. The psychrophilic microorganisms are naturally occurring bacteria, isolated from a stream in Pennsylvania, with the ability to grow at 4°C, and perhaps lower. These strains are expected to be commercially available the first week of December.

Mike Matheny, President and Owner of Envera stated, “There are applications, such as waste water treatment, pond maintenance, and soil or seed applications, where our products must work in low temperature environments.” “The addition of this group of bacteria to our microbial portfolio will greatly increase the breadth of our temperature activity range,” added Matheny. “These strains are also showing promise at temperatures below 4°C,” concluded Matheny.

The bacteria covered in the patent are listed as Bacillus sp. This decision was made because the bacteria did not match well to any existing species. Genetic analysis using 16S ribosomal RNA indicated the closest matches were Bacillus simplex or Bacillus butanolivorans. Further testing in the laboratory revealed some major biochemical differences between the newly described Envera strains and the Bacillus simplex and Bacillus butanolivorans type strains.

“I am excited that we may have isolated a new species,” stated co-inventor Dr. Zivile Panaviene. “We are performing additional genetic and biochemical studies to finalize the speciation of these isolates,” added Zivile. “We have 6-12 months of research ahead of us to answer that question, but we are committed to finding the answer,” finished Dr. Panaviene.

“Envera is continually isolating and testing new environmental microbial isolates,” commented Matheny. “We have taken this approach because most of the strains in publically accessible culture collections have been extensively tested, and those strains with positive attributes are available to everyone,” added Matheny. “Envera’s approach is to perform our own microbial isolations to build a proprietary culture collection containing unique organisms with extraordinary attributes,” continued Matheny. “Discovering a group of bacteria with exceptional capabilities, and that may be a new species, is further validation of Envera’s business model,” Matheny added. “We are preparing additional patent filings to cover a number of proprietary microbial strains we isolated over the last few years,” concluded Matheny.

Envera is a bioscience-based company focused on the production of environmentally friendly products. With decades of experience in the isolation, large scale production, stabilization and product formulation of microorganisms, Envera is a leader in the development and commercialization of microbial and enzyme based products for the consumer, institutional, agricultural, waste water, and bioremediation markets. Envera’s technology platform includes expertise in the areas of bacteriology, mycology, enzymology, and chemistry.

Contact: Michael Matheny at mmatheny(at)envera(dot)com or phone 484-593-4002 for more information.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11349076.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Envera Increases Scientific Staff
2. Envera Appoints Michael McErlean Fermentation Manager
3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
4. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
5. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
6. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
7. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
8. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
9. Ronald L. Chez Files Amended 13D and Letter to the Board
10. China Cord Blood Corporation Files its Annual Report on Form 20-F
11. Regulus Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Neurotrope, Inc. ... therapies for neurodegenerative diseases, including Alzheimer,s disease, today ... application to list the Company,s common stock on ... The NASDAQ Stock Market, a unit of the ... will ring the Opening Bell at the NASDAQ ...
(Date:3/24/2017)... BEIJING , March 24, 2017 Sinovac Biotech Ltd. ... products in China , today announced that its ... the expiration date of the plan from March 27, 2017 to ... proposal. About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is ...
(Date:3/23/2017)... Malden, MA (PRWEB) , ... March 23, 2017 ... ... as, “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, ... AxioMed disc polymer exhibits properties to gently absorb compressive forces and return to ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
Breaking Biology Technology:
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):